Lifevantage Corporation (LFVN)
NASDAQ: LFVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LFVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $52.63M
- P/E (TTM)
- 19.76
- Forward P/E
- 27.67
- EPS (TTM)
- $0.21
- Dividend yield
- 4.58% ($0.19)
- Ex-dividend date
- Dec 1, 2026
- 52-week range
- 3.90 – 11.71
- Day range
- 4.00 – 4.93
- Volume / Avg
- 72.94K / 45.72K
- Beta
- —
- Shares outstanding
- 12.68M
52-week range
LFVN stock today
On Nov 20, LFVN ended the session at $4.15, shedding $0.74 (15.13%), versus the S&P 500's 3.70% decline. At this level, LFVN sits near the bottom of its 52-week range of $3.90 to $11.71: 64.6% below the high, set on Jun 2, 2026 and 6.4% above the low. LFVN is down 32.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.5%.
Lifevantage trades at 19.8x its trailing twelve-month earnings per share of $0.21. Its forward P/E of 27.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. To receive the next $0.05 dividend, investors must own shares before the Dec 1 ex-dividend date.
Summary generated from market data by MetaCap's automated system. Methodology
About Lifevantage
Company profileLifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. It also provides anti-aging skin care products, such as liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, and hand creams, as well as shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Terrence O. Moorehead
- Headquarters
- Lehi, UT
- Employees
- 209
- Website
- lifevantage.com
Financial highlights
Full financialsIn fiscal 2026, Lifevantage generated $182.6 million in revenue, down 20.1% from fiscal 2025, its first annual decline since 2024. Net income was $5.1 million (-48.3% year over year), for a net margin of 2.8% versus a median of 1.5% in the prior 5 years. Gross margin was 77.6% (down from 80.4%) and operating margin 3.3%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $182.59M | $228.53M | $200.16M | $213.40M | $206.36M |
| Growth | -20.10% | +14.17% | -6.20% | +3.41% | -6.28% |
| Net income | $5.07M | $9.80M | $2.94M | $2.54M | $3.12M |
| EPS (diluted) | $0.40 | $0.75 | $0.23 | $0.20 | $0.24 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$7.50+80.72%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $0.18 vs $0.03
- Surprise
- +500.00%
Dividends
Dividend history- Annual dividend
- $0.19
- Dividend yield
- 4.58%
- Last payment
- $0.05
- Ex-dividend date
- Dec 1, 2026
- Pay date
- Dec 15, 2026
LFVN news
All LFVN news- LifeVantage Corporation Reports Voting Results from Fiscal Year 2027 Annual MeetingNasdaq
- LifeVantage (LFVN) Q1 2027 Earnings Call TranscriptNasdaq
- Lifevantage (LFVN) Surpasses Q1 Earnings EstimatesNasdaqLFVN, COO
- LifeVantage Declares Quarterly DividendGlobeNewswire
- Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue EstimatesNasdaqBDX, LFVN
- McKesson (MCK) Beats Q2 Earnings and Revenue EstimatesNasdaqMCK, LFVN
- LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026GlobeNewswire
- LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Lifevantage peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs LFVN |
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs LFVN |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs LFVN |
| ALDXAldeyra Therapeutics Inc. | 0.84 | +16.39% | $50.70M | vs LFVN |
| CLNNClene Inc. | 3.52 | +0.57% | $50.69M | vs LFVN |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs LFVN |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs LFVN |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs LFVN |
Indexes, lists and sector
Lifevantage stock FAQ
What is Lifevantage's stock price today?
LFVN last traded at $4.15 as of Nov 20, 4:00 PM EST, down 15.13% on the day. Prices are delayed at least 15 minutes.
Does Lifevantage pay a dividend?
Yes. Lifevantage pays $0.19 per share annually, a 4.58% yield. The most recent dividend of $0.05 had an ex-dividend date of Dec 1, 2026.
What is LFVN's P/E ratio?
LFVN trades at a trailing P/E ratio of 19.76 and a forward P/E of 27.67.
Who is Lifevantage's CEO?
Mr. Terrence O. Moorehead is the chief executive officer of Lifevantage Corporation, which has about 209 employees.
Has LFVN ever split its stock?
Yes. The most recent LFVN stock split was a 1-for-7 split on Oct 19, 2015, one of 2 splits on record.
What is the LFVN 52-week high?
The 52-week high for LFVN is $11.71 and the 52-week low is $3.90. The stock is currently 64.6% below its high.